Welcome to the University of Colorado Movement Disorders Center!
The Movement Disorders Center (MDC) is a nationally recognized center for specialty care of those with movement disorders. The MDDC is headquartered at the University of Colorado Anschutz Medical Campus (CU Anschutz) in Aurora, CO. The campus is the largest health center in the Rocky Mountain Region.
The University of Colorado has a long, distinguished history of excellence in this area, including the first and largest trial of cell transplantation for Parkinson’s disease, the development of the most widely used speech therapy for Parkinson’s disease, groundbreaking works in the description of Fragile-X Ataxia Syndrome, development of the first palliative care clinic in the United States focused on movement disorders, and one of the largest deep brain stimulation surgery centers in the country.
The mission of the MDC is to excel in the care of movement disorders patients and related research. We accomplish this mission by:
- providing world-class clinical care to patients.
- conducting cutting-edge interdisciplinary research.
- serving as a regional and national leader in educating movement disorders professionals.
- serving as a regional leader in community involvement for patient advocacy and education.
The MDC is the Rocky Mountain region’s largest specialty care provider for more than 7,000 patients annually. In addition to our outpatient visits, our practitioners provide specialized services. Those services include deep brain stimulation, high-intensity focused ultrasound, opportunities to participate in clinical trials, botulinum toxin injections, physical therapy, occupational therapy, speech therapy, neuropsychological testing, and psychiatric services.
The MDS has been at the forefront of movement disorders research with the first and largest clinical trial of stem cells as treatment for Parkinson’s disease, the development of the leading voice therapy for Parkinson’s disease (Lee Silverman Voice Treatment), and playing a key role in the initial description of Fragile X Ataxia Syndrome.
Our team engages in a wide variety of educational activities which include mentoring graduate, medical, post-doctoral students, and neurology residents; educating the next generation of movement disorders neurologists through our fellowship program; and providing education events for local primary care physicians and neurologists.
The MDC is the Rocky Mountain region’s largest provider of specialty care for more than 7,000 patients annually. In addition to our outpatient visits, our practitioners provide specialized services. Those services include deep brain stimulation surgery, opportunities to participate in clinical trials, botulinum toxin injections, physical therapy, occupational therapy, speech therapy, neuropsychological testing, and psychiatric services.
The MDC has been at the forefront of movements disorders research with the first and largest clinical trial of stem cells as a treatment for Parkinson’s disease, development of the leading voice therapy for Parkinson’s disease (Lee Silverman Voice Treatment), and playing a key role in the initial description of Fragile X Ataxia Syndrome.
Our team engages a wide variety of educational activities which include mentoring graduate, medical, and post-doctoral students and neurology residents, educating movement disorders specialists through our fellowship program, and providing Continuing Medical Education (CME) events for local primary care physicians and neurologists.
The physicians and other practitioners of the MDC are leaders in community outreach. They speak to support groups and work with the region’s movement disorders community organizations to provide the most up-to-date information. The MDC also hosts annual educational symposia for patients, care partners, and families.
The Movement Disorders Center was founded in 2012 to provide state-of-the-art interdisciplinary clinical care and community outreach to patients and families in the Rocky Mountain region, to pursue research, to treat and prevent these disorders, and to educate care partners and families. The center was designated a Huntington’s Disease Society of America Center of Excellence in 2015, a Parkinson’s Foundation Center of Excellence in 2019, and a National Ataxia Foundation Center of Excellence in 2024.
We look forward to serving your healthcare needs.
